5008752025-04-012025-06-305008752025-06-305008752025-04-012025-06-30in-capmkt:OtherExpenses1Member5008752025-04-012025-06-30in-capmkt:OtherExpenses2Member5008752025-04-012025-06-30in-capmkt:ReportableSegments1Member5008752025-04-012025-06-30in-capmkt:ReportableSegments2Member5008752025-04-012025-06-30in-capmkt:ReportableSegments3Member5008752025-04-012025-06-30in-capmkt:ReportableSegments4Member5008752025-04-012025-06-30in-capmkt:ReportableSegments5Member5008752025-04-012025-06-30in-capmkt:ReportableSegments1Member5008752025-04-012025-06-30in-capmkt:ReportableSegments2Member5008752025-04-012025-06-30in-capmkt:ReportableSegments3Member5008752025-04-012025-06-30in-capmkt:ReportableSegments4Member5008752025-04-012025-06-30in-capmkt:ReportableSegments5Member5008752025-04-012025-06-30in-capmkt:ReportableSegments1Member5008752025-06-30in-capmkt:ReportableSegments1Member5008752025-04-012025-06-30in-capmkt:ReportableSegments2Member5008752025-06-30in-capmkt:ReportableSegments2Member5008752025-04-012025-06-30in-capmkt:ReportableSegments3Member5008752025-06-30in-capmkt:ReportableSegments3Member5008752025-04-012025-06-30in-capmkt:ReportableSegments4Member5008752025-06-30in-capmkt:ReportableSegments4Member5008752025-04-012025-06-30in-capmkt:ReportableSegments5Member5008752025-06-30in-capmkt:ReportableSegments5Member5008752025-04-012025-06-30in-capmkt:ReportableSegments1Member5008752025-06-30in-capmkt:ReportableSegments1Member5008752025-04-012025-06-30in-capmkt:ReportableSegments2Member5008752025-06-30in-capmkt:ReportableSegments2Member5008752025-04-012025-06-30in-capmkt:ReportableSegments3Member5008752025-06-30in-capmkt:ReportableSegments3Member5008752025-04-012025-06-30in-capmkt:ReportableSegments4Member5008752025-06-30in-capmkt:ReportableSegments4Member5008752025-04-012025-06-30in-capmkt:ReportableSegments5Member5008752025-06-30in-capmkt:ReportableSegments5Member5008752025-04-012025-06-30

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

5008752025-04-012025-06-30

ItemsThatWillBeReclassifiedToProfitAndLoss1

iso4217:INRiso4217:INRxbrli:shares

500875

ITC

NOTLISTED

INE154A01025

ITC Limited

Main Board

Equity

2025-04-01

2026-03-31

2025-08-01

2025-07-18

INR

Crores

Quarterly

First quarter

Multi segment

2025-08-01

14:30:00

2025-08-01

17:05:00

Not applicable

2025-04-01

2025-06-30

Unaudited

Consolidated

231293500000

6822100000

238115600000

62383000000

38941900000

979900000

16758500000

164700000

4229600000

44065500000

167523100000

70592500000

17385900000

460100000

17846000000

52746500000

687600000

53434100000

2140800000

55574900000

52442000000

992100000

54582800000

992100000

12517500000

4.19

4.18

4.19

4.18

1. ‘Revenue from operations’ includes ‘Gross Revenue from sale of products and services’ and ‘Other operating revenue’. 2. ‘Purchase of stock-in-trade’ should be read as ‘Purchase of Stock-in-Trade and Biological Assets’. 3. ‘Changes in inventories of finished goods, work-in-progress and stock-in-trade’ should be read as ‘Changes in inventories of finished goods, Stock-in-Trade, work-in-progress, intermediates and Biological Assets’. 4. ‘Depreciation, depletion and amortisation expense’ should be read as ‘Depreciation and amortization expense’. NOTES TO STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2025 1. The unaudited Consolidated Financial Results and Segment Results were reviewed by the Audit Committee, and approved by the Board of Directors of the Company at its meeting held on 1st August, 2025. 2. The continuing significant brand building costs covering a range of personal care and branded packaged food products are reflected under 'Other expenses' stated above and in Segment Results under 'FMCG-Others'. 3. 34,22,360 Ordinary Shares of Re. 1/- each were issued and allotted under the Company’s Employee Stock Option Schemes during the quarter ended 30th June, 2025. Consequently, the issued and paid-up Share Capital of the Company stands increased to Rs. 1251,75,42,141/- as on 30th June, 2025. 4. The Group on 21st May, 2025 acquired 594 Equity Shares of Rs. 10/- each and 2,201 Compulsorily Convertible Preference Shares of Rs. 10/- each of Mother Sparsh Baby Care Private Limited (Mother Sparsh), an associate company, consequent to which the Group’s shareholding in Mother Sparsh aggregated 39.47% of its share capital on a fully diluted basis. 5. The Group on 13th June, 2025 acquired the entire share capital of Sresta Natural Bioproducts Private Limited (SNBPL), consequent to which SNBPL became a wholly owned subsidiary of the Company and its subsidiaries viz., Fyve Elements LLC, USA and Sresta Global FZE, UAE, became step-down wholly owned subsidiaries of the Company with effect from the said date. The fair values of assets and liabilities acquired have been provisionally determined and recorded in accordance with Ind AS 103 on ‘Business Combinations’ and have been reflected in ‘FMCG – Others’ segment. Accordingly, financial results of the Group and ‘FMCG-Others’ segment for the quarter ended 30th June, 2025 include those of SNBPL and its subsidiaries from 13th June, 2025 and hence are not comparable with previous periods. 6. The Board of Directors of the Company at the meeting held today i.e. 1st August, 2025 has approved, subject to necessary approvals, the Scheme of Amalgamation of Sresta Natural Bioproducts Private Limited and Wimco Limited, wholly owned subsidiaries, with the Company under Sections 230 and 232 of the Companies Act, 2013. 7. Discontinued Operations represents operations of the Hotels Business of the Group (excluding ITC Grand Central, Mumbai) which was demerged pursuant to the Scheme of Arrangement amongst the Company and ITC Hotels Limited and their respective shareholders and creditors under Sections 230 to 232 read with the other applicable provisions of the Companies Act, 2013 (‘the Scheme’) w.e.f. 1st January, 2025, being the Appointed Date and the Effective Date of the Scheme. Comparative information has been presented accordingly. Brief particulars of the Discontinued Operations are given as under (Rs. in Crores): Sr. No. - Particulars - 3 Months ended 30.06.2025 (Unaudited) - Corresponding 3 Months ended 30.06.2024 (Unaudited) - Preceding 3 Months ended 31.12.2025 (Audited) - Twelve Months ended 31.03.2025 (Audited) a - Revenue from Operations - 0 - 700.40 - 0 - 2484.58 b - Total Income - 0 - 712.58 - 0 - 2517.16 c - Total Expenses - 0 - 593.91 - 0 - 2002.67 d – Share of Profit / (Loss) of Associates and Joint Ventures - 0 - 3.85 - 0 - 11.35 e - Profit Before Exceptional Items and Tax (b-c+d) - 0 - 122.52 - 0 - 525.84 f - Exceptional Items - 0 - (3.04) - 15145.18 - 15128.81 g - Tax Expenses - 0 - 34.81 - 492.57 - 638.64 h - Profit from Discontinued Operations (e+f-g) - 0 - 84.67 - 14652.61 - 15016.01 8. This statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Excise Duty

16345600000

Other Expenses

27719900000

FMCG - Cigarettes

95538600000

FMCG - Others

58004400000

Agri Business

97238400000

Paperboards, Paper & Packaging

21166200000

Others

11825900000

283773500000

53698600000

230074900000

FMCG - Cigarettes

54989300000

FMCG - Others

3990300000

Agri Business

4346700000

Paperboards, Paper & Packaging

1514000000

Others

1548800000

66389100000

164700000

-5055700000

71280100000

FMCG - Cigarettes

106084600000

FMCG - Others

167240600000

Agri Business

102602900000

Paperboards, Paper & Packaging

100220500000

Others

31214000000

507362600000

444283500000

951646100000

FMCG - Cigarettes

62160200000

FMCG - Others

26826600000

Agri Business

17154100000

Paperboards, Paper & Packaging

13784500000

Others

10826100000

130751500000

60075800000

190827300000

1. ‘Revenue from operations’ should be read as ‘Gross Revenue from sale of products and services’. 2. ‘Other Unallocable Expenditure net off Unallocable income’ should be read as ‘Other un-allocable (income) net of un-allocable expenditure (Refer Note)’. 3. In case of 3 months ended 30.06.2025, ‘Other Unallocable Expenditure net off Unallocable income’ includes ‘Other un-allocable (income) net of un-allocable expenditure (Refer Note)’ of Rs. (436.81) Crores, and ‘Share of Profit / (Loss) of associates and joint ventures’ of Rs. 68.76 Crores. 4. In case of 3 months ended 30.06.2025, ‘Un-allocable Assets’ includes Nil ‘Discontinued Operations*’ and ‘Unallocated Corporate Assets’ of Rs. 44428.35 Crores. 5. In case of 3 months ended 30.06.2025, ‘Un-allocable Liabilities’ includes Nil ‘Discontinued Operations*’ and ‘Unallocated Corporate Liabilities’ of Rs. 6007.58 Crores. * Refer note 7 to the Consolidated Financial Results. Note: As stock options and stock appreciation linked reward units are granted to align the interests of employees with those of shareholders and also to attract and retain talent for the Group as a whole, the charge thereof do not form part of the segment performance reviewed by the Corporate Management Committee.

Items that will not be reclassified to profit or loss

1870100000

271900000

Items that will be reclassified to profit or loss

625300000

82700000

2140800000